These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35419291)

  • 1. The Inflammatory Status of Soluble Microenvironment Influences the Capacity of Melanoma Cells to Control T-Cell Responses.
    Bogéa GMR; Silva-Carvalho AÉ; Filiú-Braga LDC; Neves FAR; Saldanha-Araujo F
    Front Oncol; 2022; 12():858425. PubMed ID: 35419291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
    Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
    Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.
    Gestermann N; Saugy D; Martignier C; Tillé L; Fuertes Marraco SA; Zettl M; Tirapu I; Speiser DE; Verdeil G
    Oncoimmunology; 2020; 9(1):1736792. PubMed ID: 32850194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.
    Davern M; Bracken-Clarke D; Donlon NE; Sheppard AD; Connell FO; Heeran AB; Majcher K; Conroy MJ; Mylod E; Butler C; Donohoe C; Donnell DO; Lowery M; Bhardwaj A; Ravi N; Melo AA; Sullivan JO; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6583-6599. PubMed ID: 36790524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
    Ziogas DC; Theocharopoulos C; Lialios PP; Foteinou D; Koumprentziotis IA; Xynos G; Gogas H
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
    Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
    Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
    Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
    Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
    Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
    J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
    Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
    Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.
    López González M; van de Ven R; de Haan H; van Eck van der Sluijs J; Dong W; van Beusechem VW; de Gruijl TD
    Clin Exp Immunol; 2020 Aug; 201(2):145-160. PubMed ID: 32301504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.